Clinical trials: Cough Frequency
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant.
- Trial name
- NCT03449134
- Testing
- Gefapixant
- Where
- 156 sites in United States, Argentina and 15 more
- Volunteers
- 732 people
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Does tiotropium effect the cough reflex in patients with COPD and chronic bronchitis.
- Trial name
- NCT00870896
- Testing
- Tiotropium
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- ThomasTruncale
Bacterial Infections, Virus Diseases
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
This study will determine whether three manufacturing lots of V419 (PR5I) induce similar immune responses to all of the antigens contained in V419 when given concomitantly with Prevnar13™ and RotaTeq™.
- Trial name
- NCT01340937
- Testing
- V419, PENTACEL™, Prevnar 13™
- Volunteers
- 2,808 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cough, Superior Laryngeal Nerve Block
Efficacy of SLN Block for Chronic Cough
This is a research study to find out if superior laryngeal nerve blocks are an effective way to reduce cough when compared to placebo (a substance without any medical value).
- Conditions
- Cough, Superior Laryngeal Nerve Block, Neurogenic Cough
- Trial name
- NCT04421092
- Testing
- Superior laryngeal nerve block, Injection of steroid-lidocaine mixture
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine.
- Trial name
- NCT01480258
- Testing
- PR5I, Rotavirus vaccine, Prevenar 13™
- Volunteers
- 1,315 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Cough
Bronchial Hyper-responsiveness in Reflux Cough
The study aim is to determine the effect of 8 weeks of anti-reflux treatment (full acid suppression) on bronchial hyper-responsiveness and whether there is a symptomatic improvement.
- Trial name
- NCT00668317
- Testing
- Omeprazole, Ranitidine
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant.
- Trial name
- NCT03449147
- Testing
- Gefapixant 15 mg BID, Gefapixant 45 mg BID
- Where
- 171 sites in United States, Australia and 18 more
- Volunteers
- 1,317 people
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00303316
- Testing
- DTaP-IPV//PRP~T combined vaccine
- Where
- Argentina
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Sanofi
Refractory/Unexplained Chronic Cough
ATP Level and Cough Sensitivity to ATP in Subjects With Refractory/Unexplained Chronic Cough
This is a cross-sectional study to investigate ATP level in induced sputum and cough sensitivity to ATP in subjects with refractory/unexplained chronic cough.
- Trial name
- NCT05265871
- Where
- China
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Kefang Lai
Spinal Cord Injuries, Spinal Cord Diseases
Spinal Cord Stimulation to Restore Cough
The purpose of this trial is to determine the efficacy of spinal cord stimulation to produce an effective cough in patients with spinal cord injuries.
- Conditions
- Spinal Cord Injuries, Spinal Cord Diseases, Paralysis, Central Nervous System Diseases
- Trial name
- NCT00116337
- Testing
- Spinal Cord Stimulation to restore cough, Expiratory Muscle Stimulator
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- MetroHealth Medical Center
Diphtheria, Tetanus
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00404651
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-HBV-IPV vaccine
- Where
- 6 sites in Mexico
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Refractory Chronic Cough
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
- Trial name
- NCT03282591
- Testing
- 5 mg Serlopitant Tablets
- Where
- 39 sites in United States, United Kingdom
- Volunteers
- 185 people
- Sponsor
- Vyne Therapeutics Inc.
Refractory Chronic Cough
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
This study is designed to evaluate the efficacy of three dose regimens of gefapixant ([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough frequency.
- Trial name
- NCT02612610
- Testing
- Gefapixant
- Volunteers
- 253 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Immunization; Infection, Pregnancy Related
Increasing Influenza and Tdap Vaccination of Pregnant Women
Pregnant women who get influenza are more likely than non-pregnant women to have serious complications, including hospitalizations, death, preterm labor and premature birth.
- Trial name
- NCT04444518
- Testing
- VAX-MOM Intervention, Standard of Care
- Where
- United States
- Volunteers
- 12,760 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Idiopathic Pulmonary Fibrosis
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause that results in scarring of the lungs. Cough is reported by 85% of patients with IPF and can be a distressing symptom with significant physical, social and…
- Trial name
- PAciFy Cough (NCT04429516)
- Testing
- Morphine Sulfate
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00337428
- Testing
- Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF), Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF), Comparator: REPEVAX™ (Concomitant)
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acute Respiratory Infection
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
- Trial name
- MCC/CC (NCT01114581)
- Testing
- Mucinex
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Reckitt Benckiser LLC
Diphtheria, Tetanus
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Objectives: To present the rates of adverse reactions after a dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT00802867
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
- Where
- 19 sites in United States
- Volunteers
- 989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Primary Objective: To demonstrate that the immune response of the DTaP-IPV-Hep B-PRP~T is non-inferior for all valences to those of the association of PENTAXIM™ and ENGERIX B® PEDIATRICO one month after a three-dose primary…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00831311
- Testing
- DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
- Where
- Argentina
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company